ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
+25.85%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$277M
AUM Growth
+$277M
(-4.2%)
Cap. Flow
-$71.8M
Cap. Flow
% of AUM
-25.9%
Top 10 Holdings %
Top 10 Hldgs %
46.86%
Holding
81
New
21
Increased
12
Reduced
18
Closed
26
Top Buys
| 1 |
Becton Dickinson
BDX
|
$17.3M |
| 2 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
$8.49M |
| 3 |
Cencora
COR
|
$7.66M |
| 4 |
Smith & Nephew
SNN
|
$7.55M |
| 5 |
Elutia
ELUT
|
$5.56M |
Top Sells
| 1 |
Encompass Health
EHC
|
$16.8M |
| 2 |
AdaptHealth
AHCO
|
$13.8M |
| 3 |
Integra LifeSciences
IART
|
$13.3M |
| 4 |
AbbVie
ABBV
|
$12.3M |
| 5 |
Ocular Therapeutix
OCUL
|
$11.3M |
Sector Composition
| 1 | Healthcare | 93.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OXFD
1
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $39.1M | 14.11% | 2,240,421 +485,956 | +28% | +$8.49M |
|
|
2
Becton Dickinson
BDX
$55.3B
| $17.3M | 6.25% | +69,264 | New | +$17.3M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $15.1M | 5.46% | 244,066 -146,090 | -37% | -$9.06M |
|
|
TRIL
4
DELISTED
Trillium Therapeutics Inc.
TRIL
| $9.65M | 3.48% | 655,741 +283,340 | +76% | +$4.17M |
|
|
5
AbbVie
ABBV
$372B
| $9.06M | 3.27% | 84,544 -114,377 | -57% | -$12.3M |
|
6
Johnson & Johnson
JNJ
$427B
| $8.85M | 3.19% | 56,231 -18,748 | -25% | -$2.95M |
|
7
OrthoPediatrics
KIDS
$536M
| $7.96M | 2.87% | 193,008 +66,244 | +52% | +$2.73M |
|
|
8
Cencora
COR
$56.5B
| $7.66M | 2.76% | +78,339 | New | +$7.66M |
|
9
SI-BONE Inc
SIBN
$719M
| $7.62M | 2.75% | 254,907 -208,243 | -45% | -$6.23M |
|
|
10
Smith & Nephew
SNN
$16.3B
| $7.55M | 2.72% | +179,138 | New | +$7.55M |
|
11
Aclaris Therapeutics
ACRS
$209M
| $7.29M | 2.63% | 1,126,675 -306,142 | -21% | -$1.98M |
|
12
Elevance Health
ELV
$71.8B
| $7.27M | 2.62% | 22,634 +4,725 | +26% | +$1.52M |
|
|
SYNH
13
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $6.95M | 2.51% | 101,953 -10,198 | -9% | -$695K |
|
|
MTEM
14
DELISTED
Molecular Templates, Inc.
MTEM
| $6.4M | 2.31% | 681,243 +258,456 | +61% | +$2.43M |
|
15
Fate Therapeutics
FATE
$120M
| $6.06M | 2.18% | 66,585 +10,375 | +18% | +$943K |
|
|
16
Encompass Health
EHC
$12.3B
| $6.05M | 2.18% | 73,104 -203,001 | -74% | -$16.8M |
|
|
17
Ocular Therapeutix
OCUL
$2.12B
| $6.01M | 2.17% | 290,465 -546,672 | -65% | -$11.3M |
|
|
ADAP
18
Adaptimmune Therapeutics
ADAP
$15.6M
| $5.81M | 2.1% | 1,078,177 +503,675 | +88% | +$2.71M |
|
|
19
AdaptHealth
AHCO
$1.28B
| $5.65M | 2.04% | 150,414 -367,963 | -71% | -$13.8M |
|
|
20
Elutia
ELUT
$96.7M
| $5.56M | 2.01% | +408,213 | New | +$5.56M |
|
21
Owens & Minor
OMI
$378M
| $5.53M | 1.99% | +204,384 | New | +$5.53M |
|
22
Avantor
AVTR
$9.18B
| $5.48M | 1.98% | +194,777 | New | +$5.48M |
|
23
Esperion Therapeutics
ESPR
$448M
| $5.39M | 1.94% | 207,293 +71,392 | +53% | +$1.86M |
|
24
Cigna
CI
$80.3B
| $5.22M | 1.88% | 25,085 -42,376 | -63% | -$8.82M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $4.84M | 1.74% | +28,378 | New | +$4.84M |
|